• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home 2MM Trial Briefs

FDA accepted an application to review at-home use of dexmedetomidine for agitation in schizophrenia and bipolar disorder

by2 Minute MedicineandReviewed by Andrew Cheung, MD MBA (McMaster University)
November 17, 2026
in 2MM Trial Briefs, Neurology, Pharma, Psychiatry
Reading Time: 2 mins read
Schizophrenia collage: a calm young man, a side-view drawing of the brain, a weekly pill organizer and a potted plant
Share on FacebookShare on TwitterShare on LinkedIn

1. The Food and Drug Administration (FDA) accepted BioXcel Therapeutics’ supplemental New Drug Application (sNDA) for at-home use of dexmedetomidine, but has not approved the use.

2. The SERENITY III phase 3 trial enrolled 452 participants; registry results report no efficacy or safety findings.

Evidence Rating Level: 2 (Good)

2MM Brief: BioXcel Therapeutics reported that the FDA accepted its sNDA seeking at-home use of IGALMI (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. Acceptance initiates regulatory review; it is not an approval. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026. IGALMI is currently described by the company as a prescription medicine administered under the supervision of a health care provider for this indication. The company’s application concerns use in the at-home, or outpatient, setting, for which the source states there is currently no FDA-approved treatment option. The supporting registry entry describes SERENITY III (NCT05658510) as a phase 3 study sponsored by BioXcel Therapeutics, with enrollment of 452 and a completed status. The registry lists the primary outcome as Part 1 change from baseline in the Positive and Negative Syndrome Scale – Excited (PEC) total score. However, the available registry entry provides design information only and does not report efficacy estimates, confidence intervals, P values, follow-up duration, or safety results. The company’s materials state that the safety and efficacy of the investigational at-home use have not been established. They also state that IGALMI’s safety and effectiveness have not been studied beyond 24 hours from the first dose and list sleepiness or drowsiness, oral prickling or numbness, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing among the most common side effects in clinical studies. The regulatory announcement has not been peer reviewed, and the application remains under FDA review. These materials establish a regulatory milestone and identify a completed supporting trial, but they do not establish whether at-home dexmedetomidine is effective or safe for this use; the FDA’s review and reported clinical results will be needed to clarify its status.

FDA approvedFor schizophrenia: Bysanti (milsaperidone), Feb 20, 2026→

Citation

© 2026 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: © 2 Minute Medicine

RELATED REPORTS

Dexmedetomidine (Precedex) may offer similar analgesic efficacy as remifentanil (Ultiva) with fewer adverse effects in adults undergoing sleeve gastrectomy

WHO launches 2026 global initiative to bridge the schizophrenia mortality gap

Tags: agitationBipolar DisorderdexmedetomidineIGALMIschizophreniaSERENITY III
Previous Post

In a randomized sham-controlled trial, acupoint thread embedding produced a between-group difference in change from baseline of 1.8 kg at 12 weeks and 3.0 kg at 24 weeks in Chinese women with overweight or obesity

RelatedReports

Robotic surgical instruments with surgical mesh and sutures, indicating a procedure for hernia repair.
Gastroenterology

Dexmedetomidine (Precedex) may offer similar analgesic efficacy as remifentanil (Ultiva) with fewer adverse effects in adults undergoing sleeve gastrectomy

October 6, 2026
Jessica Lau
Psychiatry

WHO launches 2026 global initiative to bridge the schizophrenia mortality gap

September 4, 2026
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
Chronic Disease

The Scan by 2 Minute Medicine®: TikTok “Fibermaxxing” trend targets gut microbiome diversity, Jennifer Aniston’s “Strength for 50+” ritual spotlights photobiomodulation, American Lung Association issues respiratory warning over viral “mouth taping” fad, and Psychiatric Times highlights initiative to close the schizophrenia mortality gap

April 22, 2026
Pain control after surgery collage: an older woman resting on a hospital pillow beside a teal nerve that branches at one end
Chronic Disease

Subcutaneous dexmedetomidine may safely improve refractory pain and delirium in hospice patients

January 13, 2026
✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • FDA accepted an application to review at-home use of dexmedetomidine for agitation in schizophrenia and bipolar disorder
  • In a randomized sham-controlled trial, acupoint thread embedding produced a between-group difference in change from baseline of 1.8 kg at 12 weeks and 3.0 kg at 24 weeks in Chinese women with overweight or obesity
  • PROT-001 was generally safe and well tolerated in a phase 1 study of healthy volunteers with AL amyloidosis
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.